Healthcare Economist September 16, 2021
Getting from a mRNA COVID-19 vaccine to scaling to manufacture these vaccines for billions of people is far from simple:
Manufacturing mRNA vaccines for the first time in a very short timeframe required significant innovation and remains a technically challenging endeavor. The process proved to be technically challenging as Pfizer developed a 50,000 step process. Pfizer identified and worked with 86 different suppliers. The vaccine required 280 materials in total, 10 to 15 of which were novel to the mRNA vaccine. Through unstinting effort and investment, Pfizer cut the initial production time in half, enabling it...
Today's Sponsors
Today's Sponsor